Dengue fever (DF) is an endemic infectious disease in tropical and subtropical regions. Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen on B cells, which is approved for the treatment of both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS). We describe the favorable clinical outcome of DF in an RRMS patient treated with Ocrelizumab, who neither presented hemorrhagic or systemic shock symptoms nor reported neurological worsening.
DelignyCde BandtMDehlingerV, et al. Dengue fever in patients under biologics. J Clin Virol2014; 61(3): 442–443.
3.
BolloLGuerraTBavaroDF, et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J Neurol Sci2020; 416: 117011.
4.
JuanateyABlanco-GarciaLTellezN.Ocrelizumab: Its efficacy and safety in multiple sclerosis. Rev Neurol2018; 66(12): 423–433.
5.
Tiga-LozaDCMartínez-VegaRAUndurragaEA, et al. Persistence of symptoms in dengue patients: A clinical cohort study. Trans R Soc Trop Med Hyg2020; 114: 355–364.
6.
GelfandJMCreeBACHauserSL.Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics2017; 14: 835–841.
7.
PriyamvadaLChoAOnlamoonN, et al. B cell responses during secondary dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J Immunol2016; 90: 5574–5585.
8.
ChangalKHRainaAHRainaA, et al. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: An observational hospital based clinico-serological study from North India. BMC Infect Dis2016; 16: 715.
9.
SouzaNCSEFélixACde PaulaAV, et al. Evaluation of serological cross-reactivity between yellow fever and other flaviviruses. Int J Infect Dis2019; 81: 4–5.
10.
LiGHNingZJLiuYM, et al. Neurological manifestations of dengue infection. Front Cell Infect Microbiol2017; 7: 449.
11.
FragosoYDda GamaPDGomesS, et al. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Mult Scler Relat Disord2016; 6: 64–65.
